Abstracts Archive - Page 243 of 2607 - ACR Meeting Abstracts

Abstract Number: 0489 • ACR Convergence 2024
Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis
Hannah Brubeck¹, Kylie Riggles², Riley Bass³, Elizabeth Wahl⁴, James Andrews⁵, Namrata Singh⁶, ariela orkaby⁷, Joshua Baker⁸, Patti Katz⁹, Dolores Shoback¹⁰, Jose Garcia¹¹ and Katherine Wysham¹², ¹VA Puget Sound Health Care System, Seattle, WA, ²VA Puget Sound Health Care System, Bellevue, WA, ³VA Puget Sound Health Care System, Seattle, ⁴VA Puget Sound Healthcare System, Seattle, WA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Washington, Bellevue, WA, ⁷New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹UCSF, San Rafael, CA, ¹⁰San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System/University of Washington, Seattle, WA, ¹²VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty occurs earlier in people with rheumatoid arthritis (RA) than in the general population and is associated with poor health outcomes1, making it important…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0482 • ACR Convergence 2024
Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis
Vanshika Sabharwal¹ and Ashit Syngle², ¹MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India, ²Healing Touch City Clinic, Chandigarh, Chandigarh, India
Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…
Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Monique Bastidas¹, Lythou Yeo¹, Susie Magpantay¹, Judah Scott¹, Mike Zikry¹, Wayne Galdamez¹, Jane Yang² and Kelly Chun¹, ¹Labcorp, Calabasas, CA, ²LabCorp, Weston, MA
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
Abstract Number: 0431 • ACR Convergence 2024
Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
Abraham Yair Lujano-Negrete¹, Lorena Perez-Barbosa², Conrado Garcia³, CASSANDRA SKINNER TAYLOR⁴, Jose Hernandez Linas³, Adriana Lobato-Belmonte³, Yesenia Ambriz Murillo⁵, Alfonso Gastelum-Strozzi⁶, Amaranta Manrique de Lara⁷, Ana Rodriguez-Flores⁸, Jesus Cardenas-de la Garza⁹, Marco Maradiaga-Cecena¹⁰, Galilea Rodriguez Orozco¹¹, Anahí Carrazco Chapa¹¹, Dionicio Galarza-Delgado¹² and Ingris del Pilar Pelaez Ballestas³, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, ¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, ²Hospital Universitario, UANL, Monterrey, Mexico, ³Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, ⁴HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁵Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, ⁶Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, ⁷Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, ⁸Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ¹⁰Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, ¹¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ¹²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 2545 • ACR Convergence 2024
Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Shuhei Takeyama¹, Michihito Kono¹, Kohei Karino¹, Yuki Kudo¹, Masatoshi Kanda², Hiroyuki Nakamura², Kenichi Miyamoto¹, Kazuro Kamada³, Maria Tada¹, Ryo Hisada¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Department of Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapprp, Japan, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most severe organ manifestations in SLE and is associated with poor quality of life. We…
Abstract Number: 0502 • ACR Convergence 2024
Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
Gerd Burmester¹, Jakub Trefler², Artur Racewicz³, Janusz Jaworski⁴, Agnieszka Zielińska⁵, Marek Krogulec⁶, Sławomir Jeka⁷, Rafał Wojciechowski⁸, Katarzyna Kolossa⁹, Anna Dudek¹⁰, Magdalena Krajewska-Włodarczyk¹¹, Paweł Hrycaj¹², Piotr Adrian Klimiuk¹³, SungHyun Kim¹⁴, JeeHye Suh¹⁴, GoEun Yang¹⁴, Yunah Kim¹⁴, YooBin Jung¹⁴, JiWoo Hong¹⁴ and Josef Smolen¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²REUMA RESEARCH, Wrocław, Poland, ³Zdrowie Osteo-Medic, Warszawa, Poland, ⁴Reumatika-Centrum Reumatologii, Warszawa, Poland, ⁵MICS Centrum Medyczne Warszawa, Warszawa, Poland, ⁶NZOZ Lecznica MAK - MED, Nadarzyn, Poland, ⁷MICS Centrum Medyczne, Polska, Poland, ⁸Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, ⁹MICS Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland, ¹⁰Centrum Medyczne Amed, Warszawa, Poland, ¹¹University of Warmia and Mazury, Clinic of Rheumatology, Olsztyn, Poland, ¹²Prywatna Praktyka Lekarska Prof. dr hab. med. Paweł, Poznań, Poland, ¹³Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, ¹⁴Celltrion, Inc., Incheon, Republic of Korea, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: The therapeutic equivalence of CT-P47 (a proposed biosimilar to reference tocilizumab [ref-tocilizumab]) was demonstrated in patients with moderate to severe RA through disease activity…
Abstract Number: 0386 • ACR Convergence 2024
Variability of Data Completeness and Consensus Treatment Plan Adherence for Polyarticular Juvenile Idiopathic Arthritis Patients Within the Childhood Arthritis and Rheumatology Research Alliance Registry
Daniel Glaser¹, Cagri Yildirim-Toruner², Stacey Tarvin³, Stacy Ardoin⁴ and Timothy Beukelman⁵, and the CARRA Registry Investigators, ¹Yale University School of Medicine, New Haven, CT, ²Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a large observational registry of children and young adults with childhood-onset rheumatic disease. The Registry is…
Abstract Number: 0499 • ACR Convergence 2024
PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment
Wanki Ho¹, Huaqun Zhu¹, Hua Ye¹, Dongdong Fu² and Xi Xu¹, ¹Peking University People's Hospital, Beijing, China, ²Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)
Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
Abstract Number: 0432 • ACR Convergence 2024
Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
Marion couderc¹, celine lambert², sabrina hamroun³, denis gallot⁴, Nathalie Costedoat-chalumeau⁵, Laure Gossec⁶, Gaëlle Guettrot-Imbert⁷, Veronique LE GUERN⁷, Christophe Richez⁸, MArtin Soubrier⁹ and Anna Molto¹⁰, ¹CHU de Clermont-Ferrand, Clermont-Ferrand, ²chu clermont ferrand, clermont ferrand, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, ⁵University Paris Cité, Paris, France, ⁶Sorbonne Université, Paris, France, ⁷Cochin Hospital, Paris, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁰Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Joan Merrill¹, Amit Saxena², Martin Aringer³, Yoshiya Tanaka⁴, Xiaofeng Zeng⁵, Peter Wung⁶, Ling Cheng⁶, Thao Doan⁶, Shelly Kafka⁶, David DCruz⁷ and Kristin D'Silva⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ²NYU Grossman School of Medicine, New York, NY, ³University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁶AbbVie Inc., North Chicago, IL, ⁷The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].